Wellbutrin and Weight Loss: What the FDA Label Says

Quick answer

As of September 2026, Wellbutrin XL (bupropion hydrochloride extended-release) is FDA-approved for exactly 2 uses by its own label: treatment of major depressive disorder and prevention of seasonal affective disorder. It is not FDA-approved for weight management. The label mentions weight only in its adverse reactions section, where it reports a dose-related decrease in body weight in depression trials and lists anorexia (loss of appetite) among commonly observed adverse reactions. The only FDA-approved weight-management product containing bupropion is Contrave, which pairs bupropion with naltrexone and carries its own label and boxed warning. Whether bupropion in any form is appropriate for you is a decision for a licensed physician who knows your history.

What is Wellbutrin XL approved for?

The clearest way to answer "does Wellbutrin cause weight loss" is to start where the FDA starts: the prescribing information. Section 1 of the Wellbutrin XL label, published by Bausch Health, says "Wellbutrin XL is an aminoketone antidepressant, indicated for" two things: "treatment of major depressive disorder (MDD)" and "prevention of seasonal affective disorder (SAD)".

That is the whole list. There is no weight-management indication, no obesity indication, and no appetite indication anywhere on the label. The Medication Guide that comes with the prescription says the same thing in plain words: "Wellbutrin XL is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder and for the prevention of autumn-winter seasonal depression (seasonal affective disorder)."

Bupropion is the active ingredient, so searches for "bupropion weight loss" and "Wellbutrin weight loss" point to the same label. It also appears in Wellbutrin SR, Aplenzin, Forfivo XL and Zyban, and the label warns against taking more than one bupropion-containing product at once. Our guide on how to read a prescription label walks through the indication section and the rest.

Does Wellbutrin cause weight gain or weight loss, according to its label?

Weight is discussed in the label, but in the adverse reactions section, not in the indications. Adverse reactions are effects observed in clinical trials or reported after marketing. They are not treatment goals, and a listing in that section is not an approved indication.

Under the heading "Changes in Body Weight," the label states, about the short-term depression trials of the sustained-release formulation: "There was a dose-related decrease in body weight." For the seasonal affective disorder trials, it reports that "A higher proportion of subjects in the bupropion group" had weight loss "compared to the placebo group." Both tables are titled "Incidence of Weight Gain or Weight Loss" and record participants who gained weight as well as participants who lost it, so the label treats this as a two-directional observation, not a promise in either direction. We are leaving the label's figures out on purpose: they come from trials run to study depression, and quoting them as if they answered a weight question would be misleading.

The list of commonly observed adverse reactions also includes "anorexia," which in label language means loss of appetite. So the honest reading is this: the label observed weight change as a side effect in trials run for a different purpose. It does not describe bupropion as a weight-loss medicine, and it does not tell physicians how to use it as one.

What is the boxed warning on Wellbutrin XL?

Wellbutrin XL, like other antidepressants, carries the FDA's most prominent safety statement, a boxed warning, and it is about suicidal thoughts and behaviors. Other antidepressants carry the same boxed warning, and what the Cymbalta label says about weight reads the duloxetine label the same way. The Wellbutrin XL boxed warning reads: "Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials." It directs that "In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors."

This matters for the weight question because the warning applies whenever bupropion is prescribed, for any reason.

Who should not take Wellbutrin XL, according to the label?

Section 4 lists the contraindications, the situations in which the drug should not be used at all. In plain words, Wellbutrin XL is contraindicated in people who:

• have a seizure disorder;
• have "a current or prior diagnosis of bulimia or anorexia nervosa," because "a higher incidence of seizures was observed in such patients treated with Wellbutrin XL";
• are abruptly stopping alcohol, benzodiazepines, barbiturates or antiepileptic drugs;
• are taking a monoamine oxidase inhibitor (MAOI) for a psychiatric condition, or have stopped one within the interval the label specifies, including linezolid and intravenous methylene blue;
• have a known hypersensitivity to bupropion or any ingredient of the product.

The eating-disorder contraindication deserves attention in an article about weight. A history of disordered eating is exactly the kind of thing a physician needs to know before any conversation about this medicine.

What warnings does the label carry beyond the box?

Section 5, Warnings and Precautions, groups the label's other safety concerns. Without the numbers, the categories are:

• Neuropsychiatric events during smoking cessation. The label describes postmarketing reports that "have included changes in mood (including depression and mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, aggression, hostility, agitation, anxiety, and panic" as well as suicidal ideation and behavior.
• Seizure. "Wellbutrin XL can cause seizure. The risk of seizure is dose-related." Among the "predisposing conditions" that raise the risk, the label names "use of anorectic drugs," meaning appetite suppressants. Combining bupropion with an appetite suppressant is something the label itself flags.
• Hypertension. "Wellbutrin XL can increase blood pressure. Monitor blood pressure before initiating treatment and periodically during treatment."
• Activation of mania or hypomania. The label tells prescribers to screen for bipolar disorder before starting.
• Psychosis and other neuropsychiatric reactions, angle-closure glaucoma, and hypersensitivity reactions, including anaphylactic reactions and Stevens-Johnson syndrome, which the label says have been reported.

What adverse reactions and drug interactions does the label name?

The label's summary line lists the most common adverse reactions from the depression trials as "dry mouth, nausea, insomnia, dizziness, pharyngitis, abdominal pain, agitation, anxiety, tremor, palpitation, sweating, tinnitus, myalgia, anorexia, urinary frequency, rash." We are not repeating the label's frequencies, because rates from a depression trial do not transfer to a different population or purpose, and the label itself cautions that trial rates "may not reflect the rates observed in practice."

Section 7, Drug Interactions, names these groups: CYP2B6 inducers such as ritonavir, efavirenz, carbamazepine and phenytoin; drugs metabolized by CYP2D6, because bupropion "can increase concentrations of" certain antidepressants, antipsychotics, beta-blockers such as metoprolol, and Type 1C antiarrhythmics; drugs that lower the seizure threshold; dopaminergic drugs (levodopa and amantadine); MAOIs, with an increased risk of hypertensive reactions; and a laboratory interaction, since Wellbutrin XL "can cause false-positive urine test results for amphetamines." If you take any medicine on this list, it belongs in the first sentence of your conversation with a physician.

Is there an FDA-approved weight-loss medicine that contains bupropion?

Yes, one. Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release), whose prescribing information is published by Nalpropion Pharmaceuticals, is the only bupropion-containing product with a weight-management indication. Its label, section 1, reads: "CONTRAVE is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition." Naltrexone, the other active ingredient in that product, carries a separate label of its own, and naltrexone's own approved uses are alcohol dependence and opioid blockade rather than weight.

Three things about Contrave are easy to miss when people ask "is Contrave the same as Wellbutrin":

1. It is a different product with a different approval. Contrave's own boxed warning states that it "is not approved for use in the treatment of major depressive disorder or other psychiatric disorders". The FDA approved the combination for weight management; it did not approve Wellbutrin for weight management. Neither label stands in for the other.
2. The two cannot be taken together. The Contrave label lists "Use of other bupropion-containing products (including, but not limited to, WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL, APLENZIN and ZYBAN)" among its contraindications.
3. It carries its own restrictions. Contrave is contraindicated in uncontrolled hypertension, seizure disorder or a history of seizures, bulimia or anorexia nervosa, chronic opioid use, abrupt withdrawal from alcohol or sedatives, MAOI use and known allergy to either ingredient. Its label also states a limitation of use: "The effect of CONTRAVE on cardiovascular morbidity and mortality has not been established."

What does "off-label" mean, and who decides?

The FDA explains the term on its patient-information page "Understanding Unapproved Use of Approved Drugs 'Off Label'": "From the FDA perspective, once the FDA approves a drug, healthcare providers generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient."

The same page describes what approval gives you: "That FDA has conducted a careful evaluation of its benefits and risks for that use." An off-label use does not come with that evaluation. It rests on the judgment of a licensed physician, who weighs the evidence, the label's warnings and the person in front of them.

Two consequences follow. First, no website, including this one, can tell you that Wellbutrin "works for weight loss," because the agency that reviews such claims has not made that finding. Second, an off-label prescription is not a product to request; it is a conclusion a physician may or may not reach after an evaluation. A diabetes medicine makes the point in another therapeutic area: a look at the Jardiance prescribing information finds body weight only among the measurements taken in trials run for blood sugar. The same logic applies to other medicines discussed for weight outside their labels, such as topiramate for weight loss and Trulicity for weight loss.

How does a physician evaluate the question?

The label gives a physician a checklist, in the order it is written:

• Is there an approved reason? If depression or seasonal affective disorder is present, treating it is the goal, and any weight effect is a side effect to monitor, not a target.
• Is anything contraindicated? Seizure history, past or present eating disorder, abrupt withdrawal from alcohol or sedatives, MAOI use, and allergy each close the door according to the label.
• What about blood pressure and mood history? The label calls for blood pressure monitoring and screening for bipolar disorder.
• Would an approved weight-management product fit better? If the goal is weight management and the person meets a label's criteria, the physician can consider those products on their own terms.

Where do FDA-approved weight-management medicines fit?

Several products carry an explicit weight-management indication. Contrave is one. Wegovy (semaglutide), a GLP-1 receptor agonist, is another: its label indicates it "in combination with a reduced calorie diet and increased physical activity" to "reduce excess body weight and maintain weight reduction long term" in adults with obesity and in adults with overweight who have at least one weight-related condition, among the groups its label names.

The difference between these products and Wellbutrin is not that one "works" and the other does not. It is that the FDA reviewed the weight-management data for Contrave and Wegovy and wrote it into their labels, with the indication, limitations, warnings and monitoring that go with it. Wellbutrin's label was reviewed for depression. To understand the GLP-1 class from the label up, start with what a GLP-1 medication is and Wegovy alternatives.

Questions to bring to a physician

• Do I have a diagnosis that matches one of Wellbutrin XL's approved uses?
• Have I ever had a seizure, or a diagnosis of anorexia nervosa or bulimia at any point in my life?
• Which of my current medicines appear in the label's drug-interaction section?
• Is my blood pressure controlled, and is there any history of bipolar disorder or mania in me or my family?
• If weight management is my actual goal, which products carry that indication on their label, and do I meet their criteria?
• If a medicine is prescribed off-label, what evidence is the decision based on, and what would make us stop?

This article is for informational purposes only and does not constitute medical advice. Medication is prescribed only if a licensed physician determines it is appropriate. Label text quoted above was read from the FDA-approved prescribing information current as of September 2026; labels change, and the current version on DailyMed governs.